Research article summary (published 6 Sep 2009):

A cell-permeable peptide inhibits hepatitis C virus replication by sequestering IRES transacting factors.

Full Abstract

Hepatitis C virus (HCV) infection frequently leads to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. There is no effective therapy or vaccine available to HCV-infected patients other than interferon-ribavarin combination, which is effective in a relatively small percentage of infected patients. Our previous results have shown that a synthetic peptide (LAP) corresponding to the N-terminal 18 amino acids of the Lupus autoantigen (La) was a potent inhibitor of HCV IRES-mediated translation. We demonstrate here that LAP efficiently blocks HCV replication of infectious JFH1 virus in cell culture. Our data suggest that LAP forms complexes with IRES-transacting factors (ITAFs) PTB and PCBP2. LAP-mediated inhibition of HCV IRES-mediated translation in vitro could be fully rescued by recombinant PCB and PCBP2. Also transient expression of PTB / PCBP2 combination significantly restores HCV replication in LAP-inhibited cultures. These results suggest that ITAFs could be potential targets to block HCV replication.

Author information

Author/s: Fontanes, Vanessa (V); Raychaudhuri, Santanu (S); Dasgupta, Asim (A);

Affiliation: Department of Microbiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

Grants: AI-38056 (Agency:NIAID NIH HHS) ; AI-45188 (Agency:NIAID NIH HHS) ; AI-45733 (Agency:NIAID NIH HHS)

Journal and publication information

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal: Virology (Virology), published in United States. (Language: eng)

Reference: 2009-Nov; vol 394 (issue 1) : pp 82-90

Dates: Created 2009/10/26; Completed 2009/11/05;

PMID: 19740508, status: MEDLINE (last retrieval date: 11/5/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antiviral Agents - pharmacokinetics; pharmacology Autoantigens - genetics Cell Line Hepacivirus - drug effects; physiology Humans Peptides - pharmacokinetics; pharmacology Polypyrimidine Tract-Binding Protein - antagonists & inhibitors; metabolism

Polypyrimidine Tract-Binding Protein - antagonists & inhibitors; metabolism Protein Binding Protein Biosynthesis - drug effects RNA, Viral - metabolism RNA-Binding Proteins - antagonists & inhibitors; metabolism Ribonucleoproteins - genetics Virus Replication - drug effects

Associated Chemicals: Antiviral Agents (0) ; Autoantigens (0) ; PCBP2 protein, human (0) ; Peptides (0) ; RNA, Viral (0) ; RNA-Binding Proteins (0) ; Ribonucleoproteins (0) ; SS-B antigen (0) ; Polypyrimidine Tract-Binding Protein (139076-35-0)

Related articles

These are the highest related articles currently in the database:

• Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. 30 Jul 2005
• NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. 24 Nov 2007
• Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. 30 Jul 2005
• Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication. 23 Apr 2005
• Selective inhibitors of hepatitis C virus replication. 21 Jun 2006
• Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells. 3 Dec 2005
• Current and future therapy for chronic hepatitis C virus liver disease. 30 Aug 2003
• RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. 27 Oct 2007
• Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies. 29 Nov 2001
• The hepatitis C virus life cycle as a target for new antiviral therapies. 29 Apr 2007

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.